A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer

Human Gene Therapy

Volumn 25, Issue 12, 2014, Pages 1003-1012

  Abate Daga, Daniel ^a   Lagisetty, Kiran H ^a   Tran, Eric ^a   Zheng, Zhili ^a   Gattinoni, Luca ^a   Yu, Zhiya ^a   Burns, William R ^a   Miermont, Anne M ^a   Teper, Yaroslav ^a   Rudloff, Udo ^a   Restifo, Nicholas P ^a   Feldman, Steven A ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BLUEBIRD BIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CHIMERIC ANTIGEN RECEPTOR; COMPLEMENTARY DNA; HUMAN MONOCLONAL ANTIBODY; PROSTATE STEM CELL ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PSCA PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PLACENTA; PROSTATE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; STROMA CELL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; CYTOTOXICITY; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906508776     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.209     Document Type: Article

References (41)

1. Anurathapan, U., Chan, R.C., Hindi, H.F., et al. (2014). Kinetics of tumor destruction by chimeric antigen receptormodified T cells. Mol. Ther. 22, 623-633
2. Argani, P., Rosty, C., Reiter, R.E., et al. (2001). Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61, 4320-4324
3. Bahrenberg, G., Brauers, A., Joost, H.G., and Jakse, G. (2000). Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun. 275, 783-788
4. Brentjens, R., Yeh, R., Bernal, Y., et al. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666-668
5. Carpenito, C., Milone, M.C., Hassan, R., et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360-3365
6. Cartwright, T., Richards, D.A., and Boehm, K.A. (2008). Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 15, 308-313
7. Chmielewski, M., Hahn, O., Rappl, G., et al. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143, 1095-1107.e2
8. Di Stasi, A., Tey, S.K., Dotti, G., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683
9. Elsamman, E., Fukumori, T., Kasai, T., et al. (2006). Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int. 97, 1202-1207
10. Feldmann, G., Beaty, R., Hruban, R.H., and Maitra, A. (2007). Molecular genetics of pancreatic intraepithelial neoplasia. J. Hepatobiliary Pancreat. Surg. 14, 224-232
11. Gattinoni, L., Lugli, E., Ji, Y., et al. (2011).Ahumanmemory T cell subset with stem cell-like properties. Nat Med. 17, 1290-1297
12. Gu, Z., Thomas, G., Yamashiro, J., et al. (2000). Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288-1296
13. Gudas, J., Jakobovits, A., Jia, X., et al (2012). Antibodies and Related Molecules That Bind to PSCA Proteins (Agensys, Inc., Santa Monica, CA
14. Hillerdal, V., Ramachandran, M., Leja, J., and Essand, M. (2014). Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer 14, 30
15. Hombach, A.A., Rappl, G., and Abken, H. (2013). Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 'superstimulation.'Mol. Ther. 21, 2268-2277
16. Katari, U.L., Keirnan, J.M., Worth, A.C., et al. (2011). Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 13, 643-650
17. Kershaw, M.H., Westwood, J.A., Parker, L.L., et al. (2006). A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115
18. Kloss, C.C., Condomines, M., Cartellieri, M., et al. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 31, 71-75
19. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-Associated toxicity in a clinical trial of anti-CD19 chimeric-Antigen-receptor-Transduced T cells. Blood 119, 2709-2720
20. Koido, S., Homma, S., Takahara, A., et al. (2011). Current immunotherapeutic approaches in pancreatic cancer. Clin. Dev. Immunol. 2011, 267539
21. Lamers, C.H., Sleijfer, S., Vulto, A.G., et al. (2006). Treatment of metastatic renal cell carcinoma with autologous Tlymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22
22. Lamers, C.H., Willemsen, R., Van Elzakker, P., et al. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82
23. Leyton, J.V., Olafsen, T., Lepin, E.J., et al. (2008). Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin. Cancer Res. 14, 7488-7496
24. Leyton, J.V., Olafsen, T., Sherman, M.A., et al. (2009). Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng. Des. Sel. 22, 209-216
25. Li, Q., Verschraegen, C.F., Mendoza, J., and Hassan, R. (2004). Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res. 24, 1327-1335
26. Maliar, A., Servais, C., Waks, T., et al. (2012). Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143, 1375-1384.e1-e5
27. Maus, M.V., Haas, A.R., Beatty, G.L., et al. (2013). T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26-31
28. Morgan, R.A., Yang, J.C., Kitano, M., et al. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851
29. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., et al. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151
30. Morgenroth, A., Cartellieri, M., Schmitz, M., et al. (2007). Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67, 1121-1131
31. Ono, H., Yanagihara, K., Sakamoto, H., et al. (2012). Prostate stem cell antigen gene is expressed in islets of pancreas. Anat. Cell Biol. 45, 149-154
32. Ostermann, E., Garin-Chesa, P., Heider, K.H., et al. (2008). Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14, 4584-4592
33. Robbins, P.F., Morgan, R.A., Feldman, S.A., et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924
34. Saeki, N., Gu, J., Yoshida, T., and Wu, X. (2010). Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin. Cancer Res. 16, 3533-3538
35. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29
36. Tammana, S., Huang, X., Wong, M., et al. (2010). 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 21, 75-86
37. Wolpin, B.M., O'Reilly, E.M., Ko, Y.J., et al. (2013). Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann. Oncol. 24, 1792-1801
38. Zhao, Y., Wang, Q.J., Yang, S., et al. (2009). A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563-5574
39. Zheng, Z., Chinnasamy, N., and Morgan, R.A. (2012). Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J. Transl. Med. 10, 29
40. Zhong, X.S., Matsushita, M., Plotkin, J., et al. (2010). Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+T cellmediated tumor eradication. Mol. Ther. 18, 413-420
41. Zhou, X., Li, J., Wang, Z., et al. (2013). Cellular immunotherapy for carcinoma using genetically modified EGFRspecific T lymphocytes. Neoplasia 15, 544-553